CVS Health (CVS) PT Raised to $80 at TD Cowen

TD Cowen analyst Charles Rhyee raised the price target on CVS Health (NYSE: CVS) to $80.00 (from $73.00) while maintaining a Buy rating.

The analyst commented, "Our best idea for 2025 is CVS. While a high risk pick, we see potential upside of +40% worth it. We view '24 as a bottom for shares as CVS has set itself up for a significant MA turnaround in '25 after a successful '25 bid process and redesign of MA benefits. Despite concerns about growth in '25, we est. 6% EPS growth, but see potential for mid-teens% growth from Spec Pharm. & lower MA trend."

You May Also Be Interested In

• Terreno Realty Corp (TRNO) PT Raised to $77 at Cantor Fitzgerald on Leasing Optimism
• Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
• Deutsche Bank Downgrades Netskope (NTSK) to Hold on Valuation